Introduction

The European Medicines Agency( EMA) is working to grease decentralized clinical trials( DCTs) in the EU. DCTs are a type of clinical trial that uses remote monitoring and other technologies to allow cases to be shared in trials from their homes or other accessible locales. This approach has the implicit to make clinical trials more accessible to a wider range of cases, and to reduce the cost and time of medicine development.

The EMA’s Accelerating Clinical Trials in the EU( ACT EU) action is supporting the development of DCTs through a number of conditioning, including

Issuing guidance on the use of DCT rudiments in clinical trials
Developing a methodology roadmap to identify and prioritise crucial advances in clinical trial styles
Establishing amulti-stakeholder platform to grease dialogue between all stakeholders in the clinical trials community

The ACT EU action is a major step forward in the development of DCTs in the EU. By making it easier to conduct DCTs, the action has the implicit to accelerate the development of new drugs and ameliorate access to clinical trials for cases.